Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trials

Article Abstract:

A study was conducted to evaluate short-term effects of tolvaptan when added to standard therapy in patients hospitalized with heart failure (HF). It was observed that in patients hospitalized with HF, oral tolvaptan in addition to standard therapy including diuretics improved many, though not all, HF signs and symptoms, without serious adverse events.

Author: Burnett, John C., Jr., Gheorghiade, Mihai, Zannad, Faiez, Maggioni, Aldo P., Swedberg, Karl, Orlandi, Cesare, Grinfeld, Liliana, Udelson, James E., Cook, Thomas, Ouyang, John, Zimmer, Christopher, Konstam, Marvin A
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2007
Clinical report

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Effects of tolvaptan a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

Article Abstract:

Tolvaptan, a vasopressin antagonist, increased net fluid loss resulting in decreased body weight more effectively than standard therapy in patients hospitalized for heart failure. Tolvaptan also improved serum sodium level in patients with hyponatremia.

Author: Elkayam, Uri, Ghali, Jalal K., Adams, Kirkwood F., Gheorghiade, Mihai, O'Conner, Christopher M., Gattis, Wendy A., Barbagelata, Alejandro, Benza, Raymond L., McGrew, Frank A., Klapholz, Marc
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004
Evaluation, Hyponatremia

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Effects of tolvaptan a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

Article Abstract:

Tolvaptan, a vasopressin antagonist, increased net fluid loss resulting in decreased body weight more effectively than standard therapy in patients hospitalized for heart failure. Tolvaptan also improved serum sodium level in patients with hyponatremia.

Author: Elkayam, Uri, Ghali, Jalal K., Adams, Kirkwood F., Gheorghiade, Mihai, O'Conner, Christopher M., Gattis, Wendy A., Barbagelata, Alejandro, Benza, Raymond L., McGrew, Frank A., Klapholz, Marc
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2004

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Drug therapy, Dosage and administration, Heart failure, Vasopressin, Vasopressins
Similar abstracts:
  • Abstracts: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial
  • Abstracts: Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model
  • Abstracts: Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: The MERLIN-TIMI 36 randomized trial
  • Abstracts: Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
  • Abstracts: Effects of Estrogen with and without progestin on urinary incontinence. Estrogen and dementia
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.